ROSEN, LEADING INVESTOR COUNSEL, Encourages Datavault AI Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DVLT

Rosen Law Firm has filed class action lawsuits against Datavault AI Inc. (DVLT), Planet Fitness, Inc. (PLNT), and Erasca, Inc. (ERAS) on behalf of investors who purchased securities during specified periods. The lawsuits allege materially false and misleading statements, including overstated partnerships, inflated trading volumes, and undisclosed connections to convicted felons. Investors have until October 5, 2026 to move the court to serve as lead plaintiff.

08/08/2026, 6:34 PM • GlobeNewswire

ERASCA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important August 10 Deadline in Securities Class Action – ERAS

A securities class action lawsuit has been filed against Erasca, Inc. and its executives for allegedly making false and misleading statements about its lead oncology drug candidate ERAS-0015. The company is accused of improperly comparing its drug to a competitor's candidate and failing to disclose patent and trade secret disputes. Investors who purchased Erasca stock between January 14, 2025 and April 26, 2026 must act by August 10, 2026 to serve as lead plaintiff.

08/08/2026, 4:51 PM • GlobeNewswire

ERASCA LEAD PLAINTIFF DEADLINE AUGUST 10th: Bragar Eagel & Squire, P.C. Reminds Erasca, Inc. (ERAS) Investors with Large Losses to Contact the Firm Regarding their Rights

A class action lawsuit has been filed against Erasca, Inc. alleging that the company made false and misleading statements regarding its ERAS-0015 drug candidate. The lawsuit claims the preclinical data was based on improper comparisons and lacked reasonable basis. Following a patent infringement allegation from Revolution Medicines disclosed on April 28, 2026, Erasca's stock price declined approximately 48% from $19.15 to $9.90 per share. Investors have until August 10, 2026 to apply as lead plaintiff.

08/07/2026, 3:47 PM • GlobeNewswire

ERAS 3-DAY DEADLINE ALERT: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit– Hagens Berman

Hagens Berman is investigating securities fraud claims against Erasca, Inc. for allegedly misleading investors about its lead oncology drug ERAS-0015's competitive advantages, safety profile, and intellectual property protections. The company faces patent infringement allegations from Revolution Medicines and reported a patient death in clinical trials, triggering a $2.8 billion market capitalization loss. Investors with substantial losses can serve as lead plaintiffs with an August 10, 2026 deadline.

08/07/2026, 3:44 PM • GlobeNewswire

Important Notice to Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Insulet Corporation (NASDAQ: PODD); Power Solutions International, Inc. (NASDAQ: PSIX); and PROCEPT BioRobotics Corporation (NASDAQ: PRCT): Grabar Law Office is Investigating Claims on Your Behalf

Grabar Law Office has filed federal securities fraud class action investigations against four companies: Erasca for misleading statements about its ERAS-0015 drug candidate and undisclosed patent risks; Insulet for defective manufacturing controls leading to voluntary product corrections; Power Solutions for overstating sales demand and understating manufacturing costs; and PROCEPT BioRobotics for using undisclosed discount programs that artificially inflated sales and created excess inventory. Shareholders who purchased shares during specified periods are eligible to seek damages and corporate reforms.

08/07/2026, 9:32 AM • GlobeNewswire

Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP Before Application Deadline

Hagens Berman is investigating securities fraud claims against Erasca, Inc. for allegedly misleading investors about its lead oncology drug ERAS-0015's competitive advantages, safety profile, and intellectual property protections. The company faces patent infringement allegations from Revolution Medicines and reported a patient death in clinical trials. These disclosures in late April 2026 triggered a sharp stock decline, erasing over $2.8 billion in market capitalization. The lead plaintiff deadline is August 10, 2026.

08/05/2026, 10:27 PM • GlobeNewswire

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Pentair plc Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - PNR

Rosen Law Firm has filed class action lawsuits against Pentair plc, First Solar, Inc., and Erasca, Inc. on behalf of investors who suffered losses. The Pentair lawsuit alleges the company made false statements about its business while concealing significant inventory destocking in the Pool channel that adversely affected sales and operating income. Investors with losses exceeding $100,000 are encouraged to join the class actions before upcoming deadlines.

08/05/2026, 5:28 PM • GlobeNewswire

DEADLINE ALERT for ERAS, VIA, EMBC, Z: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

Class action lawsuits have been filed against four publicly-traded companies alleging securities fraud. Erasca faces allegations regarding misleading preclinical data comparisons; Via Transportation failed to disclose declining ARR and regulatory issues; Embecta misrepresented guidance and segment weakness; and Zillow mischaracterized its Redfin agreement and downplayed antitrust risks. Investors have until mid-August 2026 to file lead plaintiff motions.

08/05/2026, 2:45 PM • GlobeNewswire

Important Notice to Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Insulet Corporation (NASDAQ: PODD); Power Solutions International, Inc. (NASDAQ: PSIX); and PROCEPT BioRobotics Corporation (NASDAQ: PRCT): Grabar Law Office is Investigating Claims on Your Behalf

Grabar Law Office has launched investigations into potential securities fraud and fiduciary duty breaches at four major companies: Erasca (ERAS) for misleading statements about its ERAS-0015 drug candidate and undisclosed patent risks; Insulet (PODD) for defective manufacturing controls leading to voluntary product corrections; Power Solutions International (PSIX) for overstating sales demand and understating manufacturing costs; and PROCEPT BioRobotics (PRCT) for using undisclosed discount programs that artificially inflated sales figures and created excess inventory.

08/04/2026, 11:49 AM • GlobeNewswire

MONDAY DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - ERAS

Robbins Geller Rudman & Dowd LLP is seeking a lead plaintiff for a securities class action lawsuit against Erasca, Inc. The lawsuit alleges that Erasca made false and misleading statements regarding its ERAS-0015 drug candidate, including improper comparisons to competitor Revolution Medicines' technology and undisclosed patent infringement risks. Following disclosure of a patent infringement letter and adverse clinical trial data on April 27, 2026, Erasca's stock price fell approximately 59% combined. The deadline to apply as lead plaintiff is August 10, 2026.

08/04/2026, 7:55 AM • GlobeNewswire

ERASCA LEAD PLAINTIFF DEADLINE AUGUST 10th: Bragar Eagel & Squire, P.C. Reminds Erasca, Inc. (ERAS) Investors with Large Losses to Contact the Firm Regarding their Rights

A class action lawsuit has been filed against Erasca, Inc. alleging the company made false statements about its ERAS-0015 drug candidate based on improper comparisons and lacking reasonable basis. Following a patent infringement allegation from Revolution Medicines disclosed on April 28, 2026, Erasca's stock price plummeted 48% from $19.15 to $9.90 per share. Investors have until August 10, 2026 to apply as lead plaintiff.

08/03/2026, 6:27 PM • GlobeNewswire

FSLR DEADLINE: ROSEN, A LONGSTANDING FIRM, Encourages First Solar, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – FSLR

Rosen Law Firm is notifying investors in First Solar, PicS N.V., and Erasca of upcoming lead plaintiff deadlines in securities class action lawsuits. First Solar faces allegations of making false statements regarding tariff policy management and production facility impacts. The firm is encouraging investors who purchased securities during specified class periods to seek legal counsel.

08/02/2026, 4:49 PM • GlobeNewswire

PICS DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages PicS N.V. Investors to Secure Counsel Before Important August 4 Deadline in Securities Class Action – PICS

Rosen Law Firm is notifying investors of securities class action lawsuits against PicS N.V., Erasca, Inc., and Planet Fitness, Inc. The PicS lawsuit alleges false statements in IPO documents regarding credit evaluation procedures, loan quality, and undisclosed financial deterioration. Lead plaintiff deadlines are August 4, 2026 for PicS and August 10, 2026 for Erasca.

08/02/2026, 2:51 PM • GlobeNewswire

ERASCA DEADLINE: ROSEN, REGARDED INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important August 10 Deadline in Securities Class Action – ERAS

Rosen Law Firm is notifying investors about multiple securities class action lawsuits. The primary focus is on Erasca, Inc., which allegedly made false and misleading statements about its lead oncology drug candidate ERAS-0015, claiming it was 'best-in-class' while failing to disclose improper comparisons to competitors and lacking reasonable basis. The firm is seeking lead plaintiffs with an August 10, 2026 deadline for Erasca and August 4, 2026 for PicS N.V.

08/02/2026, 2:36 PM • GlobeNewswire

Robbins LLP Reminds Erasca, Inc. Investors of the Pending Lead Plaintiff Deadline in the Securities Fraud Class Action; Contact the Firm to Learn About Your Rights

A securities fraud class action has been filed against Erasca, Inc. (NASDAQ: ERAS) for allegedly failing to disclose risks related to patent and trade secret violations. The lawsuit stems from Erasca's ERAS-0015 drug candidate, which Revolution Medicines claims infringes its patent and involves misappropriated trade secrets. The stock dropped from $21.49 to $19.15 per share following the disclosure on April 27, 2026. Investors have until August 10, 2026 to submit lead plaintiff papers.

07/31/2026, 10:28 AM • GlobeNewswire